Where and how are we going? Simplifying the definitive diagnosis of primary aldosteronism

Tetsuo Nishikawa; Kazuki Nakai; Yuya Tsurutani; Yoko Matsuzawa; Jun Saito; Masao Omura

doi:10.1038/s41440-024-01666-y

Where and how are we going? Simplifying the definitive diagnosis of primary aldosteronism

Hypertens Res. 2024 Jun;47(6):1735-1737. doi: 10.1038/s41440-024-01666-y. Epub 2024 Apr 8.

Authors

Tetsuo Nishikawa^{1

2}, Kazuki Nakai³, Yuya Tsurutani³, Yoko Matsuzawa^{3

4}, Jun Saito³, Masao Omura^{3

5}

Affiliations

¹ Endocrinology & Diabetes Center, Yokohama Rosai Hospital, Yokohama, Japan. tetsuon@yokohamah.johas.go.jp.
² Nishikawa Clinic, Yokohama, Japan. tetsuon@yokohamah.johas.go.jp.
³ Endocrinology & Diabetes Center, Yokohama Rosai Hospital, Yokohama, Japan.
⁴ Matsuzawa Clinic, Yokohama, Japan.
⁵ Minato Mirai Medical Square, Yokohama, Japan.

PMID: 38584160
DOI: 10.1038/s41440-024-01666-y

No abstract available

Keywords: Chemiluminescent enzyme immunoassay; Liquid chromatography-mass spectrometry/mass spectrometry; Plasma aldosterone concentration; Primary aldosteronism; Radioimmunoassay.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Aldosterone / blood
Humans
Hyperaldosteronism* / blood
Hyperaldosteronism* / diagnosis

Substances

Aldosterone